Reporting of Interaction

Dinanda J. de Jager^a Renée de Mutsert^a Kitty J. Jager^b Carmine Zoccali^c
Friedo W. Dekker^{a, b}

^aDepartment of Clinical Epidemiology, Leiden University Medical Center, Leiden, ^bERA-EDTA Registry, Department of Medical Informatics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; ^cCNR-IBIM Clinical Epidemiology and Pathophysiology of Renal Diseases and Hypertension, Renal and Transplantation Unit, Ospedali Riuniti, Reggio Calabria, Italy

Key Words

Epidemiology · Risk factors · Joint exposure · Interaction

Abstract

Interaction is the situation whereby the association of one risk factor with a certain outcome variable differs across strata of another risk factor. From a public health perspective, the assessment of interaction on an additive scale may be most relevant. Although additive models exist, logistic and Cox regression models are the most commonly used models in epidemiology. The resulting relative risks can be translated to an additive scale. The present paper presents surrogate measures to evaluate the presence of additive interaction when dealing with data on a multiplicative scale (relative risks). For a transparent presentation of interaction effects it is recommended to report the separate effect of each exposure as well as their joint effect compared to the unexposed group as joint reference category to permit evaluation of interaction on both an additive and multiplicative scale.

Copyright © 2011 S. Karger AG, Basel

Interaction between Risk Factors

Interaction is the situation whereby the association of one risk factor with a certain outcome variable differs across strata of another risk factor [1, 2]. From a public health perspective, the assessment of interaction on an additive scale may be most relevant [1, 2]. An accompanying paper shows how interaction can be examined as departure from additivity using incidence rates.

Although additive models exist, logistic and Cox regression models are the most commonly used models in epidemiology. Furthermore, the case-control study design inherently leads to multiplicative modeling. Consequently, the majority of analyses of epidemiologic data are performed on a multiplicative scale. The resulting relative risks or rate ratios, however, can be translated to an additive scale.

The aim of this paper is to recommend a transparent presentation of interaction effects and to present surrogate measures that can be used to evaluate interaction on an additive scale, using effect measures derived from multiplicative models.

Reporting of Interaction

Because the presence of interaction and its interpretation depend on the underlying scale of the statistical model that is used [3, 4], the presentation of the methods and results must clarify which statistical model and scale the authors have used to evaluate the presence of interaction in their research. For a transparent presentation of interaction effects it is recommended to report the separate effect of each exposure as well as the joint effect, each relative to the unexposed group as joint reference category (as shown in tables 1 and 2) [5, 6]. Such a two-by-four table will provide the reader with sufficient information to evaluate the presence of interaction on both an additive and multiplicative scale [6]. Botto and Khoury [5] summarized the advantages of such a table for data presentation. If possible, it is recommended to report absolute risks or rates as well.

Example with Mortality Rates

It was investigated whether a deletion in the pro-inflammatory CC-chemokine receptor 5 gene (CCR5Δ32) modulates the inflammation-driven mortality in dialysis patients [7]. To study this hypothesis, absolute all-cause mortality rates in incident dialysis patients without inflammation and without CCR5Δ32; with either inflammation or CCR5Δ32; or with both inflammation and CCR5Δ32 were compared (table 1). In absence of interaction the joint effect of inflammation and CCR5Δ32 would give rise to a mortality rate of 227/1,000 person-years (PY) (assuming additivity) or 225/1,000 PY (assuming multiplicativity). The joint effect of inflammation and CCR5Δ32 however, resulted in an all-cause mortality rate of 133/1,000 PY, which was much lower than the expected rates, indicating that interaction was present both on an additive and on a multiplicative scale. Therefore, it was concluded that CCR5Δ32 modulates the inflammation-driven mortality in dialysis patients. This example illustrates how to assess the presence of additive and multiplicative interaction when using absolute mortality rates.

Measures of Additive Interaction Derived from Multiplicative Models

Three measures have been devised by Rothman [2] to evaluate additive interaction using effect measures derived from multiplicative models, such as logistic or Cox

Table 1. Mortality rates (MR, per 1,000 PY) for all-cause mortality in incident dialysis patients with inflammation (hsCRP >10), a deletion in the pro-inflammatory CC-chemokine receptor 5 gene (CCR5Δ32) or a combination of both

Inflammation	CCR5Δ32	MR
Yes	Yes	133
Yes	No	228
No	Yes	90
No	No	91

Modified from Muntinghe et al. [7].

Expected MR assuming additivity: background rate + additional effect of inflammation + additional effect of CCR5Δ32 = 91 + (228–91) + (90–91) = 227/1,000 PY.

Expected MR assuming multiplicativity: relative effect of presence of inflammation × relative effect of CCR5Δ32 × background rate = (228/91) × (90/91) × 91 = 225/1,000 PY.

Table 2. Hazard ratios for all-cause mortality with 95% CI in 218 hemodialysis patients with inflammation (high IL-6 levels), high sTWEAK levels, or a combination of both

Inflammation	High sTWEAK levels ^a	Hazard ratio (95% CI)
Yes	Yes	4.72 (2.24–9.94)
Yes	No	2.70 (1.36–5.38)
No	Yes	0.99 (0.37–2.61)
No	No	1 (reference)

Modified from Carrero et al. [16].

^a High sTWEAK was defined as above the 66th percentile. The three measures of additive interaction can be calculated as follows: RERI = $RR_{++} - RR_{+-} - RR_{-+} + 1 = 4.72 - 2.70 - 0.99 + 1 = 2.0$; AP = $RERI/RR_{++} = 2.0/4.72 = 0.43 = 43\%$; S = $(RR_{++} - 1)/([RR_{+-} - 1] + [RR_{-+} - 1]) = (4.72 - 1)/([2.70 - 1] + [0.99 - 1]) = 2.2$.

regression models [8]. These are the relative excess risk due to interaction (RERI), the attributable proportion due to interaction (AP), and the synergy index (S) [2, 8]. To calculate these measures, a simple logistic or Cox regression model should be built. This model should include a new composite variable, containing four exposure categories. The four categories indicate (1) the reference category (background risk; no exposure, or --), (2) a category for exposure to one of the risk factors under study (–+), (3) a category for exposure to the other risk factor to be examined (+–), and (4) a category for joint exposure to both risk factors under study (++) [4, 8, 9].

Fig. 1. All-cause mortality rates per 100 PY in 19,737 patients with CKD, DM, or a combination of both. The median follow-up period for all patients was 64 months. 'Background' means all-cause mortality rate in patients without CKD, DM, or both. Modified from Tonelli et al. [17].

Subsequently, the measures to evaluate additive interaction in relative risk data [4, 8–11] can be calculated as follows ('RR', relative risk, refers to either odds ratio in a logistic regression model or hazard ratio in a Cox regression model):

(a) $RERI = RR_{++} - RR_{+-} - RR_{-+} + 1$. RERI can be interpreted as the extra risk due to interaction calculated as the difference between the (expected) effect based on the summation of the separate effects of the two risk factors under study and the (observed) effect in the joint exposure category.

(b) $AP = RERI/RR_{++}$. AP can be interpreted as the proportion of the events under study (e.g. disease or mortality) that is due to interaction among persons with both exposures. AP is often expressed as a percentage.

(c) $S = (RR_{++} - 1)/([RR_{+-} - 1] + [RR_{-+} - 1])$. S can be interpreted as the excess risk from exposure to both risk factors when interaction is present, relative to the risk from exposure when interaction is absent.

When additive interaction is absent, both RERI and AP are equal to 0 and S is equal to 1. In practice, the indices will hardly ever be exactly 0 or 1. The associated 95% confidence interval (CI) may help in deciding whether additive interaction is absent (if 0 is clearly within the 95% CI of RERI and AP or 1 is clearly within the 95% CI of S). Several methods to calculate CIs around RERI, AP, and S have been proposed. Details, including Excel sheets for calculation, can be found elsewhere [9, 10, 12–14].

The reference category should be the category with the lowest risk, since RERI, AP, and S are difficult to interpret when effects are protective [2]. It is possible to include additional terms to control for confounding in the statistical model. However, in contrast to S, RERI and AP may vary across strata defined by covariates [11]. Therefore, although some advocate RERI as the best choice of measures of additivity [15], S seems the measure of choice in assessing the presence of additive interaction in multivariate models [11].

Example with Hazard Ratios

In a study on the effects of soluble TNF-like weak inducer of apoptosis (sTNF-like weak inducer of apoptosis) plasma levels on mortality, the interaction effect between sTNF levels and the presence of inflammation in hemodialysis patients were investigated [16]. The authors conclude, based on RERI 2.0 (95% CI –0.3 to 4.3), AP (43%), and S 2.2 (95% CI 0.8–5.9), that high sTNF levels have more than additive effects on all-cause mortality in hemodialysis patients with inflammation. Table 2 provides the underlying hazard ratios and the calculation of the measures.

Implication of Additive Interaction

The joint effect of chronic kidney disease (CKD) and diabetes mellitus (DM) in the association with all-cause mortality was assessed in a cohort study of 19,737 individuals being at high risk for (first) myocardial infarction or who had previous acute coronary syndromes together with average cholesterol levels [17]. The all-cause mortality rate was lowest in subjects without both CKD and DM (background rate of 6.4/100 PY) (fig. 1). The mortality rate in subjects with CKD (background rate + additional effect of CKD of 3.9/100 PY) was slightly increased. Likewise, the mortality rate in subjects with DM (background rate + additional effect of DM of 5.2/100 PY) was increased. On top of the combined effect of background, CKD, and DM an additional effect was present. This excess effect of 3/100 PY is called the interaction effect. Assuming causality, this implies that if the occurrence of CKD could be prevented in this population, this would not only prevent the 3.9 cases per 100 PY, but in addition the 3 cases per 100 PY (i.e. in total 7 deaths in 100 persons that are followed for 1 year) would be prevented that would have occurred because of interaction between CKD and DM.

Conclusion

Measures of additive interaction (RERI, AP, S) can be derived from multiplicative models to examine the presence of interaction on an additive scale using relative risks. For a transparent presentation of interaction effects it is recommended to report the separate effect of each exposure as well as their joint effect, each relative to the

joint reference category to permit evaluation of the presence of interaction on both an additive and multiplicative scale.

Disclosure Statement

No conflicts of interest exist.

References

- 1 Greenland S, Lash TL, Rothman KJ: Concepts of interaction; in *Modern Epidemiology*. Philadelphia, Lippincott Williams & Wilkins, 2008, pp 71–83.
- 2 Rothman KJ: Measuring interactions; in *Epidemiology: An Introduction*. New York, Oxford University Press, 2002, pp 168–180.
- 3 De Mutsert R, de Jager DJ, Jager KJ, Zoccali C, Dekker FW: Interaction on an additive scale. *Nephron Clin Pract* (submitted).
- 4 De Mutsert R, Jager KJ, Zoccali C, Dekker FW: The effect of joint exposures: examining the presence of interaction. *Kidney Int* 2009; 75:677–681.
- 5 Botto LD, Khoury MJ: Commentary: facing the challenge of gene-environment interaction: the two-by-four table and beyond. *Am J Epidemiol* 2001;153:1016–1020.
- 6 Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M: Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *Epidemiology* 2007;18:805–835.
- 7 Muntinghe FL, Verduijn M, Zuurman MW, Grootendorst DC, Carrero JJ, Qureshi AR, Luttropp K, Nordfors L, Lindholm B, Brandenburg V, Schalling M, Stenvinkel P, Boeschoten EW, Krediet RT, Navis G, Dekker FW: CCR5 deletion protects against inflammation-associated mortality in dialysis patients. *J Am Soc Nephrol* 2009;20:1641–1649.
- 8 Andersson T, Alfredsson L, Kallberg H, Zdravkovic S, Ahlbom A: Calculating measures of biological interaction. *Eur J Epidemiol* 2005;20:575–579.
- 9 Hosmer DW, Lemeshow S: Confidence interval estimation of interaction. *Epidemiology* 1992;3:452–456.
- 10 Knol MJ, van der Tweel I, Grobbee DE, Numans ME, Geerlings MI: Estimating interaction on an additive scale between continuous determinants in a logistic regression model. *Int J Epidemiol* 2007;36:1111–1118.
- 11 Skronidal A: Interaction as departure from additivity in case-control studies: a cautionary note. *Am J Epidemiol* 2003;158:251–258.
- 12 Assmann SF, Hosmer DW, Lemeshow S, Mundt KA: Confidence intervals for measures of interaction. *Epidemiology* 1996;7: 286–290.
- 13 Richardson DB, Kaufman JS: Estimation of the relative excess risk due to interaction and associated confidence bounds. *Am J Epidemiol* 2009;169:756–760.
- 14 Zou GY: On the estimation of additive interaction by use of the four-by-two table and beyond. *Am J Epidemiol* 2008;168:212–224.
- 15 Li R, Chambless L: Test for additive interaction in proportional hazards models. *Ann Epidemiol* 2007;17:227–236.
- 16 Carrero JJ, Ortiz A, Qureshi AR, Martin-Ventura JL, Barany P, Heimbürger O, Maron B, Metry G, Snaedal S, Lindholm B, Egido J, Stenvinkel P, Blanco-Colio LM: Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. *Clin J Am Soc Nephrol* 2009;4:110–118.
- 17 Tonelli M, Keech A, Shepherd J, Sacks F, Tonkin A, Packard C, Pfeffer M, Simes J, Isles C, Furberg C, West M, Craven T, Curhan G: Effect of pravastatin in people with diabetes and chronic kidney disease. *J Am Soc Nephrol* 2005;16:3748–3754.